Pamidronate
Contents
Description
Pamidronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption and is used to treat various bone disorders. It has been used off-label in polyostotic fibrous dysplasia to reduce bone pain and fracture risk. Clinical studies have shown improvement in bone density and reduction in skeletal complications.
Indications & Therapeutic Use
Paget's disease of bone, hypercalcemia of malignancy, osteolytic bone metastases, polyostotic fibrous dysplasia (off-label)
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Pamidronate — GNH India
44 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Pamidronate |
| Brands | 1 brand available |
| Active Ingredient | Pamidronate disodium |
| Drug Class | Paget's disease of bone |
| Manufacturer | Novartis |
| Dosage Forms | IV infusion, 30mg, 60mg, 90mg powder for reconstitution |
| Medical Code | M05BA03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00001727 |
| Countries | 10 countries |